POLYNOVO LIMITED (PNV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PNV

PNV - POLYNOVO LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.19
Index: ASX300 | ALL-ORDS

PolyNovo is an Australian medical devices company developing and commercialising its NovoSorb technology for the treatment of burns, wounds and negative pressure wound therapy. It has been a listed company since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.285

24 Dec
2025

0.025

OPEN

$1.26

1.98%

HIGH

$1.30

758,932

LOW

$1.24

TARGET
$2.01 56.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PNV: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.9 2.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% 22.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 55.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx127.2 M
Book Value Per Share xxxxxxxxxxxxxxx12.1
Net Operating Cash Flow xxxxxxxxxxxxxxx3.9 M
Net Profit Margin xxxxxxxxxxxxxxx10.38 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx17.01 %
Return on Invested Capital xxxxxxxxxxxxxxx14.44 %
Return on Assets xxxxxxxxxxxxxxx11.11 %
Return on Equity xxxxxxxxxxxxxxx17.01 %
Return on Total Capital xxxxxxxxxxxxxxx4.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx15 M
Total Debt xxxxxxxxxxxxxxx17 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx34 M
Price To Book Value xxxxxxxxxxxxxxx9.92

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx13.9 M
Capex % of Sales xxxxxxxxxxxxxxx10.95 %
Cost of Goods Sold xxxxxxxxxxxxxxx82 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx40 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

21/10/2025

1

Outperform

$2.00

55.64%

Macquarie observes PolyNovo's 1Q26 group sales rose 33% y/y to $34.7m, with strong momentum in both the US and Rest of the World (ROW).

MTX sales accelerated to A$2.9m, making up 8% of total sales vs 6% in FY25, and continued growth is expected. The broker notes a 52% revenue skew is needed in 2Q to meet its 1H26 forecast of $72.9m.

In other update, the company stated the BARDA pivotal trial is complete, with FDA submission expected end-2025 and approval process to take 8-12 months.

Balance sheet remained solid with $23.2m cash and a new CEO, Bruce Peatey, is starting on December 1.

Outperform. Target unchanged at $2.

FORECAST
Macquarie forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.10 cents.
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 4.00 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

08/12/2025

1

Buy

$1.62

26.07%

Canaccord Genuity has transferred coverage of PolyNovo to Shane Storey due to an analyst departure and re-allocation of resources.

No change to Buy rating and $1.62 target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.40 cents.
Access Extra Coverage Research History >

PNV STOCK CHART

FNArena News on PNV

1
Weekly Ratings, Targets, Forecast Changes – 12-12-25

Dec 15 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Dec 10, 2025

Dec 10 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
4
In Brief: NRW Holdings, Aroa Biosurgery, Online Retail Winners

Sep 12 2025 - Weekly Reports
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 05-09-25

Sep 05 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
2
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
3
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
4
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
5
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
6
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
7
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
8
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
9
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
10
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia